Renal	renal	O	O
papillary	papillary	O	B_disease
necrosis	necrosis	O	S_disease
due	due	O	O
to	to	O	O
naproxen	naproxen	S_chemicals	O
.	.	O	O

A	a	O	O
31-year-old	31-year-old	O	O
man	man	O	O
with	with	O	O
rheumatoid	rheumatoid	O	B_disease
arthritis	arthritis	O	S_disease
,	,	O	O
who	who	O	O
had	had	O	O
previously	previously	O	O
been	been	O	O
treated	treated	O	O
with	with	O	O
sulindac	sulindac	O	O
,	,	O	O
fenoprofen	fenoprofen	O	O
calcium	calcium	S_chemicals	O
,	,	O	O
high	high	O	O
dose	dose	O	O
salicylates	salicylates	S_chemicals	O
and	and	O	O
gold	gold	O	O
salts	salts	S_chemicals	O
,	,	O	O
developed	developed	O	O
renal	renal	O	O
papillary	papillary	O	B_disease
necrosis	necrosis	O	S_disease
(	(	O	O
RPN	rpn	O	O
)	)	O	O
4	4	O	O
months	months	O	O
after	after	O	O
institution	institution	O	O
of	of	O	O
naproxen	naproxen	S_chemicals	O
therapy	therapy	O	O
.	.	O	O

No	no	O	O
other	other	O	O
factor	factor	O	O
predisposing	predisposing	O	O
to	to	O	O
RPN	rpn	O	O
could	could	O	O
be	be	O	O
discovered	discovered	O	O
.	.	O	O

Sulindac	sulindac	O	O
was	was	O	O
substituted	substituted	O	O
for	for	O	O
naproxen	naproxen	S_chemicals	O
and	and	O	O
no	no	O	O
further	further	O	O
adverse	adverse	O	O
renal	renal	O	O
effects	effects	O	O
occurred	occurred	O	O
over	over	O	O
the	the	O	O
next	next	O	O
12	12	O	O
months	months	O	O
.	.	O	O

We	we	O	O
review	review	O	O
previous	previous	O	O
reports	reports	O	O
linking	linking	O	O
RPN	rpn	O	O
to	to	O	O
antiinflammatory	antiinflammatory	S_chemicals	O
drug	drug	S_chemicals	B_disease
use	use	O	I_disease
and	and	O	O
discuss	discuss	O	O
possible	possible	O	O
advantages	advantages	O	O
of	of	O	O
sulindac	sulindac	O	O
in	in	O	O
patients	patients	O	O
who	who	O	O
have	have	O	O
experienced	experienced	O	O
renal	renal	O	O
toxicity	toxicity	O	O
from	from	O	O
other	other	O	O
antiinflammatory	antiinflammatory	B_chemicals	O
agents	agents	I_chemicals	O
.	.	O	O

